Kuniaki Shirao - Concepedia

Author

Kuniaki Shirao

National Cancer Center Hospital East ORCID

Also Known As

K Shirao, K. Shirao, Kuniaki SHIRAO, Kuniaki Shirao, Kuniaki shirao, Shirao, Kuniaki, Tetsuya Hamaguchi, Toshihiko Doi

241

Publications

8.8K

Citations

H-Index

Concepts

All Affiliations

National Cancer Center Hospital East National Cancer Center Oita University National Institute of Health Sciences Tokyo National Hospital

About

Kuniaki Shirao is an author at National Cancer Center Hospital East specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	53	3.1K
2	Health Sciences	8	8	157
3	Engineering	2	2	58
4	Natural Sciences	1	1	11
5	Public Health	1	1	62

Kuniaki Shirao

118

Publications

8.4K

Citations

H-Index

Page 1

	Year	Citations
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Yasuhiro Matsumura, Tsuyoshi Hamaguchi, Takashi Ura, British Journal of Cancer	2004	614
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Narikazu Boku, Seiichiro Yamamoto, Haruhiko Fukuda, The Lancet Oncology OncologyCisplatin Versus S-1Gastrointestinal OncologyMedicineRandomised Phase 3	2009	591
Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205) Atsushi Ohtsu, Yasuhiro Shimada, Kuniaki Shirao, Journal of Clinical Oncology	2002	431
Risk factors for lymph node metastasis from intramucosal gastric carcinoma Takekazu Yamao, Kuniaki Shirao, Hiroyuki Ono, Cancer	1996	305
A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation Tsuyoshi Hamaguchi, Ken Kato, Hisateru Yasui, British Journal of Cancer	2007	286
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A16 and 28 Hironobu Minami, Kimie Sai, Mayumi Saeki, Pharmacogenetics and Genomics	2007	285
Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer Narikazu Boku, Atsushi Ohtsu, Yasuhiro Shimada, Journal of Clinical Oncology	1999	263
Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer Yasuhiro Matsumura, Mitsukazu Gotoh, Kei Muro, Annals of Oncology OncologyGastrointestinal OncologyMedicinePharmacokinetic StudyPeg Immunoliposome	2004	249
Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Wasaburo Koizumi, Satoshi Tanabe, Katsunori Saigenji, British Journal of Cancer	2003	249
Haplotypes ofCYP3A4 and their close linkage withCYP3A5 haplotypes in a Japanese population Hiromi Fukushima‐Uesaka, Yoshiro Saito, Hidemi Watanabe, Human Mutation	2003	165

Page 1